Abstract：
UNASSIGNED: Among postmenopausal women, oral, ultra-low-dose continuous combined estradiol (E0.5 mg) plus dydrogesterone (D2.5 mg) reduces vasomotor symptoms (VMS).
UNASSIGNED: This study was a post hoc analysis of data from two phase 3, double-blind studies. Postmenopausal women were randomized 2:1:2 to receive E0.5 mg/D2.5 mg, E1 mg/D5 mg (not included in this analysis) or placebo for 13 weeks (European study), or randomized 1:1 to receive E0.5 mg/D2.5 mg or placebo for 12 weeks (Chinese study). Endpoints assessed in ethnicity subgroups (European and Chinese) included changes from baseline in number of hot flushes, number of moderate-to-severe hot flushes and Menopause Rating Scale (MRS) score.
UNASSIGNED: Overall, 579 women were included in the analysis (E0.5 mg/D2.5 mg, n = 288; placebo, n = 291). European and Chinese women receiving E0.5 mg/D2.5 mg experienced greater reductions from baseline in mean daily number of hot flushes and mean daily number of moderate-to-severe hot flushes at week 4, week 8 and end of treatment versus those receiving placebo. Significant improvements in the \'hot flushes, sweating\' MRS item score were reported in both European and Chinese women.
UNASSIGNED: Oral, ultra-low-dose continuous combined 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone improved VMS compared with placebo in European and Chinese postmenopausal women, with a positive impact on health-related quality of life.
UNASSIGNED: This study was a post hoc analysis of data from two phase 3, double-blind studies. Postmenopausal women were randomized 2:1:2 to receive E0.5 mg/D2.5 mg, E1 mg/D5 mg (not included in this analysis) or placebo for 13 weeks (European study), or randomized 1:1 to receive E0.5 mg/D2.5 mg or placebo for 12 weeks (Chinese study). Endpoints assessed in ethnicity subgroups (European and Chinese) included changes from baseline in number of hot flushes, number of moderate-to-severe hot flushes and Menopause Rating Scale (MRS) score.
UNASSIGNED: Overall, 579 women were included in the analysis (E0.5 mg/D2.5 mg, n = 288; placebo, n = 291). European and Chinese women receiving E0.5 mg/D2.5 mg experienced greater reductions from baseline in mean daily number of hot flushes and mean daily number of moderate-to-severe hot flushes at week 4, week 8 and end of treatment versus those receiving placebo. Significant improvements in the \'hot flushes, sweating\' MRS item score were reported in both European and Chinese women.
UNASSIGNED: Oral, ultra-low-dose continuous combined 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone improved VMS compared with placebo in European and Chinese postmenopausal women, with a positive impact on health-related quality of life.
摘要：
■在绝经后妇女中，口服,超低剂量持续联合雌二醇(E0.5mg)+地屈孕酮(D2.5mg)可减少血管舒缩症状(VMS).
■本研究是对来自两个3期双盲研究的数据的事后分析。绝经后妇女以2：1：2随机接受E0.5mg/D2.5mg，E1mg/D5mg（不包括在本分析中）或安慰剂13周（欧洲研究），或随机1：1接受E0.5mg/D2.5mg或安慰剂12周（中国研究）。在种族亚组（欧洲和中国）中评估的终点包括潮热次数相对于基线的变化，中重度潮热次数和更年期评定量表（MRS）评分。
■总的来说，579名女性被纳入分析(E0.5mg/D2.5mg，n=288；安慰剂，n=291)。与接受安慰剂的女性相比，接受E0.5mg/D2.5mg的欧洲和中国女性在第4周，第8周和治疗结束时，平均每日潮热次数和平均每日中度至重度潮热次数均较基线减少。在潮热方面有了显著的改善，在欧洲和中国女性中报告了出汗\'MRS项目评分。
■口头，在欧洲和中国绝经后妇女中，与安慰剂相比，超低剂量连续联合0.5mg17β-雌二醇和2.5mg地屈孕酮可改善VMS，对健康相关生活质量有积极影响。
■本研究是对来自两个3期双盲研究的数据的事后分析。绝经后妇女以2：1：2随机接受E0.5mg/D2.5mg，E1mg/D5mg（不包括在本分析中）或安慰剂13周（欧洲研究），或随机1：1接受E0.5mg/D2.5mg或安慰剂12周（中国研究）。在种族亚组（欧洲和中国）中评估的终点包括潮热次数相对于基线的变化，中重度潮热次数和更年期评定量表（MRS）评分。
■总的来说，579名女性被纳入分析(E0.5mg/D2.5mg，n=288；安慰剂，n=291)。与接受安慰剂的女性相比，接受E0.5mg/D2.5mg的欧洲和中国女性在第4周，第8周和治疗结束时，平均每日潮热次数和平均每日中度至重度潮热次数均较基线减少。在潮热方面有了显著的改善，在欧洲和中国女性中报告了出汗\'MRS项目评分。
■口头，在欧洲和中国绝经后妇女中，与安慰剂相比，超低剂量连续联合0.5mg17β-雌二醇和2.5mg地屈孕酮可改善VMS，对健康相关生活质量有积极影响。
